Future tests
One Platform
Multiple Diagnostic Tests
Phase 1 Diagnostic Tests
The Biosensor Platform uses Organic Thin Film Transistor (OTFT) technology, which can be printed at scale and low cost. By substituting the detection element (region A), depending on the analyte to be detected, the Biosensor can be modified to monitor a wide range of saliva-based diagnostic analytes. The Platform is being developed to test for up to 130 indications, ranging from glucose to immunological conditions and communicable diseases. We are currently developing two urgently needed innovations using the Biosensor Platform.
Future Pipeline
IMMUNOLOGY
The pilot diagnostic test will be SARS-CoV-2 and the portfolio will consist of various communicable disease tests including Hepatitis A, B & C, HIV and TORCH.
HORMONES
The first test to be developed from a hormone category is Luteinizing Hormone (LH).
BIOCHEMISTRY
The pilot diagnostic test is Saliva Glucose. The diagnostic test portfolio includes Clinical Chemistry Tests (ie. Cholesterol).
IMMUNOLOGY
The pilot diagnostic test will be SARS-CoV-2 and the portfolio will consist of various communicable disease tests including Hepatitis A, B & C, HIV and TORCH.
Biosensor Platform
BIOCHEMISTRY
TUMOR MARKERS
IMMUNOLOGY
HORMONES
NUCLEIC ACIDS
Diagnostic Test Portfolio
Clinical Chemistry Tests (i.e. Cholestrol)
Diagnostic and Staging Cancer Markers
Clinical
Immunology Tests
TORCH
HIV, AIDS
Hep A,B & C
Thyroid
Adrenal
Pituitary
Gyncecological
Andrology
Personalised Genetic Diagnostics
Phase 2: Diagnostic Test
Prostate Specific Antigen (PSA)
Luteinizing Hormons (LH)
Phase 1: Diagnostic Test
Saliva Glucose Test
SARS-CoV-2 Antibodies